GLPBio

CDK

Read More about this category

<div class="colum_1 clearer"><p>CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.</p><p>There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.</p><p>CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of <i>S. pombe</i> (Cdc2), <i>S. cerevisia</i> (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).</p></div>

Products Related to CDK(299)

  • GC67970 structure
    GC67970DD-03-156
    Purity: >98%
  • GC68455 structure
    GC68455CP681301
    CAS: 865317-32-4
    Purity: >98%
  • GC68712 structure
    GC68712AZ5576
    CAS: 2751721-40-9
    Purity: >99.00%

    AZ5576 is a potent and highly selective inhibitor of CDK9 (IC50:

  • GC68845 structure
    GC68845CDK12-IN-5
    CAS: 2651200-35-8
    Purity: >98%

    CDK12-IN-5 is a pyrazole-triazine compound that is an effective inhibitor of CDK12, with an IC50 of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC50=173 μM) and CDK9/Cyclin T1 (IC50=127 μM) at high ATP (2 mM) (WO2021116178A1).

  • GC68846 structure
    GC68846CDK1-IN-2
    CAS: 220749-41-7
    Purity: >97.00%

    CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM).

  • GC68847 structure
    GC68847CDK2-IN-13
    CAS: 101622-53-1
    Purity: >98.00%

    CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 value of 12 μM. CDK2-IN-13 can be used for cancer research.

  • GC68848 structure
    GC68848CDK4/6-IN-15
    CAS: 2078047-99-9
    Purity: >98%

    CDK4/6-IN-15 is an orally effective and selective CDK4/6 inhibitor. It can effectively inhibit cancer cell growth. CDK4/6-IN-15 blocks the cell cycle in the G1 phase and inhibits phosphorylation of retinoblastoma tumor suppressor protein (Rb) at S780 site and E2 factor (E2F)-regulated gene expression in retinoblastoma tumors.

  • GC68885 structure
    GC68885CLK1-IN-2
    Purity: >98.00%

    CLK1-IN-2 is a metabolically stable inhibitor of Clk1. It has selective activity against Clk1 with an IC50 value of 1.7 nM. CLK1-IN-2 can be used for research on tumors, Duchenne muscular dystrophy, and viral infections such as HIV-1 and influenza.

  • GC68898 structure
    GC68898CPS2
    CAS: 2756741-90-7
    Purity: >98%

    CPS2 is a highly efficient, selective, and irreversible PROTAC CDK2 degrader (IC50= 24 nM). CPS2 can be used for research on acute myeloid leukemia.

  • GC68979 structure
    GC68979DIF-3
    CAS: 113411-17-9
    Purity: >98.00%

    DIF-3 promotes the degradation of GSK-3β and reduces the expression levels of cyclin D1 and c-Myc. It inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 has a strong anti-proliferative effect on human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression.

  • GC69747 structure
    GC69747PROTAC CDK12/13 Degrader-1
    Purity: >98%

    PROTAC CDK12/13 Degrader-1 (7f) is a highly efficient and selective dual degrader of cell cycle-dependent kinases CDK12/CDK13, with DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used for breast cancer research.

  • GC69987 structure
    GC69987Tanuxiciclib
    CAS: 1983983-64-7
    Purity: >98%

    Tanuxiciclib is a cell cycle cyclin-dependent kinase (CDK) inhibitor.

  • GC69988 structure
    GC69988Tanuxiciclib trihydrochloride
    CAS: 1983984-11-7
    Purity: >98.00%

    Tanuxiciclib trihydrochloride is a cell cycle cyclin-dependent kinase (CDK) inhibitor.

  • GC71063 structure
    GC71063Akt1&PKA-IN-1
    CAS: 1334107-58-2

    Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC50 values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively.

  • GC72931 structure
    GC72931HTH-01-091 TFA
    Purity: >98.00%

    HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM.

  • GC72951 structure
    GC72951CDK9 inhibitor HH1
    CAS: 204188-41-0
    Purity: >99.50%

    CDK9 inhibitor HH1 is a potent and selectively CDK9 inhibitor.

  • GC73007 structure
    GC73007DB18
    CAS: 2587177-94-2
    Purity: >98.00%

    DB18 is a potent and selective inhibitor of CDC2-like kinases (CLKs), with IC50 values in the range of 10-30 nM for CLK1, CLK2 and CLK4.

  • GC73053 structure
    GC73053BSJ-03-204 triTFA
    Purity: >99.00%

    BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK.

  • GC73063 structure
    GC73063Tagtociclib hydrate
    CAS: 2733575-91-0
    Purity: >99.00%

    PF-07104091 drate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively.

  • GC73086 structure
    GC73086CDK4/6-IN-15 hydrochloride
    Purity: >99.00%

    CDK4/6-IN-15 drochloride is an orally active and selective CDK4/6 inhibitor.

  • GC73100 structure
    GC73100Senexin C
    CAS: 2375554-02-0
    Purity: >98.00%

    Senexin C is a selective and orally active CDK8/19 inhibitor.

  • GC73183 structure
    GC73183CDK8-IN-12
    CAS: 2613307-67-6
    Purity: >99.00%

    CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM.

  • GC73219 structure
    GC73219LL-K8-22
    Purity: >99.00%

    LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively.

  • GC73224 structure
    GC73224CLK1-IN-3
    CAS: 2922550-28-3
    Purity: >98.00%

    CLK1-IN-3 (compound 10ad) is a potent and selective Clk1 inhibitor, with an IC50 of 5 nM and over 300-fold selectivity for Dyrk1A.